Kestra Medical Technologies (KMTS) Bank of America Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Bank of America Global Healthcare Conference 2026 summary
14 May, 2026Business momentum and market dynamics
Achieved strong momentum in FY 2026, driven by securing over 70% payer contract coverage and expanding the sales force from 80 to 130 reps, resulting in increased productivity and market penetration.
Market growth for WCDs is robust, with the overall market expanding at 14% and the company achieving 60% growth in the last quarter, outpacing competitors.
Market share in covered territories exceeds 25-30%, with top reps reaching over 70% share in mature accounts.
The addressable market remains underpenetrated, with only one in seven eligible patients prescribed a WCD, suggesting significant runway for growth over the next five years.
Expansion into new territories is data-driven, focusing on high-prescriber areas with payer coverage, and supported by clinical specialists to accelerate account development.
Sales force strategy and productivity
Sales force expansion is carefully targeted, often splitting high-performing territories to maximize coverage and productivity without cannibalizing existing business.
New reps ramp up to 10 fittings per month within six months, with top performers exceeding 50 fittings monthly, surpassing initial productivity models.
Clinical specialists are added to support high-performing reps, further accelerating growth in established accounts.
Investments in direct-to-cardiology sales and resource allocation are guided by ZIP code-level data on fittings and insurance coverage.
Clinical data, guidelines, and innovation
The ACE-PAS post-approval study of 21,000 patients has been well received, providing strong evidence for WCD use and helping to dispel competitor myths.
New clinical data is expected to drive guideline upgrades from 2B to 2A, potentially doubling or tripling the eligible patient base within a few years.
Recent algorithm upgrades have halved false alarm rates and reduced inappropriate shocks by over 60%, further differentiating the product.
Ongoing innovation is planned across electronics, wearable, and digital platforms, with new product launches expected annually.
Latest events from Kestra Medical Technologies
- Double-digit growth fueled by clinical proof, innovation, and expanding commercial scale.KMTS
44th Annual J.P. Morgan Healthcare Conference13 Apr 2026 - Clinically proven WCD platform drives rapid growth in a $10B U.S. cardiac care market.KMTS
Company presentation18 Mar 2026 - Q3 FY26 revenue up 63% to $24.6M, gross margin 52.6%, and FY26 guidance raised to $93M.KMTS
Q3 202617 Mar 2026 - Innovative WCD platform drives rapid growth, margin expansion, and broad payor coverage.KMTS
Company presentation13 Jan 2026 - Q3 revenue up 82% to $15.1M, gross margin at 43.4%, and IPO proceeds boost growth outlook.KMTS
Q3 202527 Dec 2025 - Q2 revenue up 53% to $22.6M, gross margin at 50.6%, FY26 guidance raised to $91M.KMTS
Q2 202612 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and a new employee stock plan.KMTS
Proxy Filing2 Dec 2025 - Virtual meeting to vote on directors, auditor, and stock plan; board recommends approval.KMTS
Proxy Filing2 Dec 2025 - Rapidly scaling, clinically proven WCD platform drives growth in a $10B+ underpenetrated market.KMTS
Company Presentation1 Dec 2025